Background—Treatment of in-stent restenosis (ISR) is still challenging. In this setting, the
use of bioresorbable vascular scaffold (BVS) seems attractive because it allows drug …

Aims: The safety of BVS implantation in patients with a high risk for early thrombotic
complications has not been studied. We report on the outcomes of patients with acute …

Background: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment
option in cardiovascular medicine. Nonetheless, there is still limited data on the use of these …

Abstract Background Bioresorbable scaffold (BRS) Absorb™ clinical use has been stopped
due to higher rate of device thrombosis. Scaffold struts persist longer than 2 years in the …

Objectives: The aim of this study was to determine the risk of scaffold thrombosis (ST) after
percutaneous coronary intervention (PCI) with placement of an ABSORB bioresorbable …

Background: Bioresorbable vascular scaffold (BVS) implantation is a new, promising
treatment method of coronary artery disease. Preliminary data in patients with stable angina …

Background Potential advantages of bioresorbable scaffolds (BRS) include restoration of
vasomotor function, endothelial function, and positive remodelling following their complete …

Aims: The aim of this study was to analyse the procedural results and midterm safety of
everolimus-eluting bioresorbable vascular scaffolds (BVS) used for percutaneous coronary …

Aims We sought to determine the impact of post-dilation (PD) on clinical outcomes in a large
cohort of patients treated only with the Absorb Bioresorbable Vascular Scaffold (BVS) …

Aims In the drug-eluting stent (DES) era, patients with acute coronary syndrome (ACS) had a
higher risk of early stent thrombosis compared with stable patients. The present study aimed …